argenx SE (ARGX)
After hours:
| Previous close | 435.92 |
| Open | 433.66 |
| Bid | 400.00 x 1100 |
| Ask | 458.70 x 1000 |
| Day's range | 432.49 - 452.16 |
| 52-week range | 333.07 - 550.76 |
| Volume | |
| Avg. volume | 244,908 |
| Market cap | 27.33B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.10 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 561.05 |
Motley FoolThese 2 Stocks Are Falling in a Fading Rally
After making modest moves on Monday, stock index futures Tuesday morning were poised to ease lower very slightly. Zscaler (NASDAQ: ZS) shares moved lower even after what appeared to be an extremely strong quarterly financial report from the cybersecurity provider. Here's the latest on both Zscaler and Argenx for you to consider.
- Reuters
UPDATE 2-November rally in European stocks stalls after comments from ECB officials
European shares fell for a second session on Tuesday, stalling November's strong run of gains, after comments by European Central Bank policymakers dampened expectations of interest rate cuts next year. The pan-European STOXX 600 index eased 0.3%, with market heavyweights such as Novo Nordisk and LVMH falling 3.1% and 1.8%, respectively. The healthcare sector slid 1.4%, with Belgian pharmaceutical firm Argenx tumbling 10.1% to the bottom of the STOXX 600 after an advance study of its treatment for bleeding disorder failed to meet primary and secondary endpoints.
GlobeNewswireargenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
Study did not meet primary or secondary endpointsFavorable safety and tolerability profile consistent with previous clinical trials Conference call scheduled for today, November 28, 2023 at 8:30am ET (2:30pm CET) Regulated information – Inside information November 28, 2023, 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced topline results fr
